Medicaid expansion is associated with increased 1-year survival for primary malignant brain tumors

Neurooncol Adv. 2023 Mar 4;5(1):vdad022. doi: 10.1093/noajnl/vdad022. eCollection 2023 Jan-Dec.

Mantas Dmukauskas¹, Gino Cioffi^{1

2}, Corey Neff^{2

3}, Mackenzie Price^{2

3}, Kristin A Waite^{1

2}, Carol Kruchko², Justin M Barnes⁴, Quinn T Ostrom^{2

3

5

6}, Jill S Barnholtz-Sloan^{1

2

7}

¹ Trans Divisional Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.
² Central Brain Tumor Registry of the United States, Hinsdale, Illinois, USA.
³ Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.
⁴ Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
⁵ The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.
⁶ Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
⁷ Center for Biomedical Informatics and Information Technology, National Cancer Institute, Bethesda, Maryland, USA.

No abstract available